Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53abn high-risk endometrial cancer with PPP2R1A mutation might not benefit from adjuvant chemotherapy.

American journal of clinical pathology - 26 Aug 2025

Zhang Qingxia, Wang Yue, He Dan, Sun Jingyun, Li Xin, Li Dong, Dong Ying, Zhang Yan, Wang Suxia

Abstract excerpt

OBJECTIVES: Recent studies have found that high-risk endometrial cancer frequently harbors mutations in tumor suppressor genes PPP2R1A and FBXW7. This study aimed to explore the prognostic utility of these genes and their potential to predict benefit from adjuvant treatment. METHODS: Tissue samples of 121 patients with high-risk endometrial cancer were collected. PPP2R1A, FBXW7, and POLE exonuclease domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Endometrial Neoplasms

Share to F-Box-WD Repeat-Containing Protein 7

Share to Prognosis

Share to Protein Phosphatase 2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 40413719
DOI: 10.1093/ajcp/aqaf039

Genes

PPP2R1A
POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53abn high-risk endometrial cancer with PPP2R1A mutation might not benefit from adjuvant chemotherapy.PMID 40413719Read ↗

ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapy.Semantic proximity Read ↗

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.Semantic proximity Read ↗

Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options.Semantic proximity Read ↗

PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study.Semantic proximity Read ↗

Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.Semantic proximity Read ↗

The genetic landscape of endometrial clear cell carcinomas.Semantic proximity Read ↗

Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.Semantic proximity Read ↗

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.Semantic proximity Read ↗

Clinicopathological features of pathogenic, non-pathogenic, and unknown significance (NP/US) POLE mutations in endometrial carcinomas: A study based on actual worldSemantic proximity Read ↗

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.Semantic proximity Read ↗

PPP2R1A mutations are common in the serous type of endometrial cancer.Semantic proximity Read ↗

Correlation analysis of TP53 missense mutations and p53 protein expression patterns in endometrial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.